

## Certificate of Analysis

### Kit (V654A), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-733, 14-733-K, 14-733M

Parent Lot # D9BN033U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal GST-tagged, recombinant human Kit, amino acids 544–end containing the V654A mutation. Co-ordinates encompass the cytoplasmic domain (544–976) according in Swiss Prot P10721. V654A is an acquired resistance mutation which has been found in patients with gastrointestinal stromal tumours (GISTs) undergoing treatment with Imatinib. The V654A mutation is strongly correlated with imatinib resistance and rapid progression of GISTs. (Chen LL *et al.*, Cancer Research, (2004); **64**:5913-5919). Expressed in Sf21 insect cells. Purified using glutathione agarose. Purity 88.4% by SDS-PAGE and Coomassie blue staining. MW = 76.7kDa.

**Specific Activity (Parent lot# D9BN033U):** 215U/mg, where one unit of Kit (V654A) activity is defined as 1nmol phosphate incorporated into 250 $\mu$ M (GGMEDIYFEFMGGKKK) per minute at 30°C with a final ATP concentration of 100 $\mu$ M.

**Formulation:** 0.274mg/ml of enzyme in 50mM Tris/HCl pH 7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 49.7–137ng of this lot of enzyme phosphorylated 250 $\mu$ M (GGMEDIYFEFMGGKKK) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as Kit (V654A) with the translated native sequence listed on page three.



**SDS-PAGE and Coomassie Stain:** Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 $\mu$ g of active Kit (V654A).

## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **(GGMEDIYFEFMGGKKK):** Use at a final assay concentration of 250 $\mu$ M. Make up a 2.5mM stock. Add 2.5 $\mu$ l of stock per assay point.
3. **Kit (V654A), active:** Dilute with 20mM MOPS/NaOH pH 7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 49.7–137ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure: (96 well plate format):

1. Add 5 $\mu$ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 $\mu$ l of **(GGMEDIYFEFMGGKKK)**.
3. Add **2.5 $\mu$ l (49.7–137ng) Kit (V654A), active**.
4. Add 5 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
8. Transfer a 10 $\mu$ l aliquot onto the appropriate area of **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

## Certificate of Analysis

### Kit (V654A) Sequence Information

<b><u>Protein</u></b>	human Kit (V654A)
<b><u>Tags</u></b>	N-terminal GST
<b><u>Native sequence</u></b>	t237 of recombinant sequence is equivalent to T544 of native human Kit
<b><u>Accession number</u></b>	GenBank X06182

#### **Recombinant Kit (V654A) amino acid sequence:**

```

1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQ SMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSR IA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAI PQID KYLKSSKYIA WPLQG WQATF GGGDHPPKSD LEVLFQGP EF KGLRRQTYKY
241 LQKPMYEVQW KVV EINGNN YVYIDPTQLP YDHKWEFPRN RLSFGKTLGA GAFGKVV EAT
301 AYGLIKSDAA MTVAVKMLKP SAHLTEREAL MSELKVL SYL GNHMNIANLL GACTIGGPTL
361 VITEYCCYGD LLNFLRRKRD SFICSKQEDH AEAALYKNLL HSKESSCSDS TNEYMDMKPG
421 VSYVVP TKAD KRRSVRIGSY IERDVTPAIM EDELALDLE DLLSFSYQVA KGMAFLASKN
481 CIHRDLAARN ILLTHGRITK ICD FGLARDI KNDSNYVVKG NARLPVKWMA PESIFNCVYT
541 FESDVWSYGI FLWELFSLGS SPYPGMPVDS KFYKMIKEGF RMLSPEHAPA EMYDIMKTCW
601 DADPLKRPTF KQIVQLIEKQ ISESTNHIYS NLANCSPNRQ KPVDHSVRI NSVGSTASSS
661 QPLL V HDDV

```

#### **Recombinant Kit (V654A) nucleotide sequence:**

```

1 atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaaccac tcgacttctt
61 ttggaatatac ttgaagaaaa atatgaagag catttgatg agcgcgatga aggtgataaa
121 tggcgaaaca aaaagtttga attgggtttg gagtttcca atcttcctta ttatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac
241 atgttggttg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
301 gatattagat acgggtgttc gagaattgca tatagtaaag actttgaaac tctcaaagtt
361 gattttctta gcaagctacc tgaatgctg aaaatgttcg aagatcgttt atgtcataaa
421 acataattaa atggtgatca tgaacccat cctgacttca tgttgatga cgctcttgat
481 gttgttttat acatggacc aatgtgcctg gatgcgttcc caaaattagt ttgttttaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat
661 ctggaagttc tgttccaggg gccgaattc atgctagcag ggtctctga gtatgagctt
721 cccgaagacc ctgctggga gctgcctcgg gacagactgg tcttaggcaa accctggga
781 gagggctgct ttgggcagg tgtgttgcca gaggctatcg ggctggcaa ggacaaacc
841 aaccgtgtga ccaaagtggc tgtgaagatg ttgaagtggc acgcaacaga gaaagacttg
901 tcagacctga tctcagaaat ggagatgatg aagatgatcg ggaagcataa gaatatcatc
961 aacctgctgg gggcctgcac gcaggatggt cccttgatg tcatcatgga gtatgcctcc
1021 aagggcaacc tgccggagta cctgcaggcc cggaggcccc cagggctgga atactgctac
1081 aacccagacc acaaccaga ggagcagctc tcctccaagg acctggtgtc ctgcccctac
1141 caggtggccc gaggcattgga gtatctggcc tccaagaagt gcatacaccg agacctggca
1201 gccaggaatg tcctggtgac agaggacaat gtgatgaaga tagcagactt tggcctcgca
1261 cgggaacttc accacatcga ctactataaa aagacaacca acggccgact gctctggaag
1321 tggatggcac ccgaggcatt atttgaccg atctacacc accagagtga tgtgtggtct
1381 ttccgggtgc tcctgtggga gatcttact ctggggggtc cccataccc cgggtgtgct
1441 gtggaggaac ttttcaagct gctgaaggag ggtcaccgca tggacaagcc cagtaactgc
1501 accaacgagc tgtacatgat gatgcgggac tgctggcatg cagtgcctc acagagacc

```

## Certificate of Analysis

1561 accttcaagc agctggtgga agacctggac cgcacgtggg ccttgacctc caaccaggag  
1621 taa

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.